ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2593 • ACR Convergence 2024

    A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research

    Miriam Bollmann1, Oskar Landberg2, Negar Ayoubzadeh2, Charlotte A. Jonsson2, Inger Gjertsson2 and Mattias Svensson2, 1University of Gothenburg, Göteborg, Sweden, 2University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with multiple tissues contributing to its pathology, including the synovial membrane. The RA synovial membrane…
  • Abstract Number: 2619 • ACR Convergence 2024

    Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients

    Tali Eviatar1, Iftach Sagy2, Elad Brav2, Amir Bieber3, Victoria Furer4 and Ori Elkayam5, 1Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, 2Soroka Medical Cenrter, beer sheva, Israel, 3Emek Medical Center, Clalit Health Services, Raanana, Israel, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
  • Abstract Number: 2611 • ACR Convergence 2024

    Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial

    Merel Opdam1, Nathan den Broeder2, Reinout van Crevel3, Lisa Schapink4, Léon Raijmakers4, Jasper Broen5, Lise Verhoef4 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, 3Radboudumc, Nijmegen, Netherlands, 4Sint Maartenskliniek, Nijmegen, Netherlands, 5Máxima Medical Centre, Eindhoven, Netherlands

    Background/Purpose: Immunomodulatory agents (IA) are widely used for the treatment of inflammatory rheumatic diseases (IRDs). Although IA are safe and effective, management of infections and infection…
  • Abstract Number: 2616 • ACR Convergence 2024

    Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases

    Jeffrey Sparks1, Xiaosong Wang2, Pui Lee3, Kailey Brodeur4, Miao Lin5, Naomi Patel5, Yumeko Kawano6, Abigail Schiff7, Andrew King5, Jennifer Hanberg6, Shruthi Srivatsan5, Emily Kowalski6, Colebrook Johnson5, Kathleen Vanni6, Zachary Williams5, Grace Qian2, Caleb Bolden5, Kevin Mueller6, Katarina Bade6, Alene Saavedra6, Rathnam Venkat8 and Zachary Wallace9, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Boston Children's Hospital, Newton, MA, 4Boston Children's Hospital, Cumberland, RI, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital, Cambridge, MA, 8Tufts University School of Medicine, Boston, MA, 9Massachusetts General Hospital, Newton, MA

    Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
  • Abstract Number: 2638 • ACR Convergence 2024

    Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level

    Andre Lucas Ribeiro1, Sibel Aydin2, Gurjit Kaeley3, Fahmeen Afgani4, Catherine Bakewell5, Marcos Rosemffet6, Minna Kohler7, Amir Haddad8, Maria S. Stoenoiu9, Ari Polachek10, josefina marin11, Arnon Katz12 and Lihi Eder13, 1Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, 2University of Ottawa - Ottawa, Ottawa, ON, Canada, 3UF COM-J, Ponte Vedra Beach, FL, 4Women's College Hospital, Toronto, Canada, 5Intermountain Healthcare, Salt Lake City, UT, 6Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 7Massachusetts General Hospital, Boston, MA, 8Carmel Medical Centre, Haifa, Israel, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12GRAPPA - Patient Research Partner, Haifa, Israel, 13University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…
  • Abstract Number: 2603 • ACR Convergence 2024

    A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation

    Gregg Silverman1 and Laurence Morel2, 1NYU Grossman School of Medicine, New York, NY, 2Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX

    Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
  • Abstract Number: 2621 • ACR Convergence 2024

    Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records

    David Cheng1, Vidul Panickan2, Andrew Cagan3, Gregory McDermott4, Mary Jeffway3, Ying Qi5, Feng Liu3, Michael Weinblatt6, Nancy Shadick5, Tianxi Cai7 and Katherine Liao3, 1Massachusetts General Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women’s Hospital, Brookline, MA, 5Brigham and Women’s Hospital, Boston, MA, 6Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 7Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
  • Abstract Number: 2627 • ACR Convergence 2024

    Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis

    Rajdeep Pooni1, Sarah Menashe2, Melissa Oliver3, Anja Schnabel4, Eveline Wu5, Zhaoyi Wang6, Claire Yang7, Achille Marino8, Cassyanne Aguiar9, Johnathan Akikusa10, Ummusen Kaya Akca11, Beverly Almeida12, Simone Appenzeller13, Ozge Basaran14, Matthew Basiaga15, David Cabral16, Martina Capponi17, nathan Donaldson18, Bugra Egeli19, Emily Fox20, Antonella insalaco21, Ramesh Iyer22, Annette Jansson23, Inna Kostik24, Mikhail Kostik25, Leonard Kovalick26, Katia Kozu27, Sivia Lapidus28, Tzielan Lee29, Aleksander Lenert30, Kamran Mahmood31, Edoardo Marrani32, Doaa Mosa33, Alexander Mushkin34, Farzana Nuruzzaman35, Karen Onel36, Manuela Pardeo21, Trang Pham22, Lauren Potts37, Athimalaipet Ramanan38, Angelo Ravelli39, Nathan Rogers18, Ian Muse40, Micol Romano41, natalie Roseenwasser22, T. Shawn Sato42, Gabriele Simonini43, jennifer Soep18, Sara Stern44, Alexander Theos45, Lori Tucker46, Leslie Vogel2, Shima Yasin30, Katerina Bouchalova47, Alison Hendry48, Kevin Cain49, Hermann Girschick50, Fatma Dedeoglu19, Christian Hedrich51, Ronald Laxer52, Polly Ferguson30, Seza Ozen53 and Yongdong Zhao54, 1Stanford University, Berkeley, CA, 2Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, 3Riley Hospital for Children, Indiana University School of Medicine, Indianopolis, IN, 4Pediatric Rheumatology, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany, 5University of North Carolina School of Medicine, Chapel Hill, NC, 6University of Washington School of Medicine, Seattle, Seattle, WA, 7Seattle Children's Hospital, Seattle, 8ASST Gaetano Pini-CTO, Milan, Italy, Milan, Italy, 9Children's Hospital of The King's Daughters, Eastern Virginia Medical School, Norfolk, VA, 10Royal Children's Hospital, Melbourne, Australia, 11Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 12Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 13Unicamp, Campinas, SP, Brazil, 14Hacettepe University, Ankara, Turkey, 15Mayo Clinic, Rochester, MN, 16BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 17Sapienza University, Rome, Italy, 18University of Colorado School of Medicine, Aurora, CO, 19Boston Children's Hospital, Boston, MA, 20Children's Mercy Hospital, Kansas City, MO, 21IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 22University of Washington School of Medicine, Seattle, WA, 23Dr. von Hauner Children´s Hospital, Munich, Germany, 24Sanatorium for children Detskie Dyuny, Saint-Petersburg, Russia, 25Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 26The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 28Hackensack University Medical Center, Montclair, NJ, 29Stanford University School of Medicine, Palo Alto, CA, 30Carver College of Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA, 31Alder Hey Children's Hospital, Liverpool, United Kingdom, 32ERN ReCONNET center, Meyer Children's Hospital-IRCCS, Firenze, Italy, 33Mansoura University Hospital, Mansoura City, Egypt, 34Science-Research Institute of Phthisiopulmonology, Saint-Petersburg, Russia, 35Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, 36HSS, New York, NY, 37Patient Research Partner, Long Beach, CA, 38Bristol Royal Hosp for Children, Bristol, United Kingdom, 39IRCCS Giannina Gaslini, Genoa, Italy, 40Seattle Children's Research institute, Seattle, WA, 41Behcet and Autoinflammatory Disease Center, Western University, London, ON, Canada, 42University of Iowa, Iowa City, 43Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 44University of Utah, Salt Lake City, UT, 45Patient/parent partner, Washington DC, DC, 46BC Children's Hospital, Vancouver, BC, Canada, 47Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic,48Division of Medicine Middlemore Hospital Counties Manukau District Health, Auckland, New Zealand, 49University of Washington, Seattle, WA, 50Vivantes Clinic Friedrichshain, Berlin, Germany, 51University of Liverpool, Liverpool, United Kingdom, 52SickKids, Toronto, ON, Canada, 53Department of Pediatrics, Hacettepe University, Ankara, Turkey, 54Seattle Children's Research institute, Seattle, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. The diagnosis of CNO is made by recognizing typical clinical and imaging presentation and excluding…
  • Abstract Number: 2623 • ACR Convergence 2024

    Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study

    Kaveh Ardalan1, Angel Davalos2, Hwanhee Hong2, Bryce Reeve2, Christoph Hornik2, M. Athony Moody2, Donald Lloyd-Jones3, Eveline Wu4, Audrey Ward1, Rebecca Sadun5, Jeff Dvergsten6, Ann Reed2, Mark Connelly7 and Laura Schanberg8, 1Duke University School of Medicine, Durham, NC, 2Duke University School of Medicine, Durham, 3Northwestern University Feinberg School of Medicine, Chicago, 4University of North Carolina School of Medicine, Chapel Hill, NC, 5Duke University, Durham, NC, 6Duke University Hospital, Hillsborough, NC, 7Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, 8Duke University Medical Center, DURHAM, NC

    Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…
  • Abstract Number: 2582 • ACR Convergence 2024

    Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

    Iain McInnes1, Laura Coates2, Philip Mease3, Alexis Ogdie4, Arthur Kavanaugh5, Lihi Eder6, Georg Schett7, Alan Kivitz8, Nuala Brennan9, Alex Godwood9, Eva Cullen9, Kristian Reich9, Christopher Ritchlin10 and Joseph F. Merola11, 1University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5University of California San Diego, La Jolla, CA, 6University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Altoona Center for Clinical Research, Duncansville, PA, 9MoonLake Immunotherapeutics AG, Zug, Switzerland, 10Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 11UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…
  • Abstract Number: 2646 • ACR Convergence 2024

    Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries

    Yosuke Kunishita1, Urvashi Kaundal2, Martin Kerick3, Ryan Routsong4, Justin Lack4, Ami Shah5, Maureen Mayes6, Daniel Shriner7, Ayo P. Doumatey7, Amy Bentley7, Robyn Domsic8, Thomas Medsger, Jr9, Paula Ramos10, Richard Silver11, Virginia Steen12, John Varga13, Vivien Hsu14, Lesley Ann Saketkoo15, Dinesh Khanna13, Elena Schiopu16, Jessica Gordon17, Lindsey Criswell18, Heather Gladue19, Chris Derk20, Elana Bernstein21, S. Louis Bridges17, Victoria Shanmugam22, Lorinda Chung23, Suzanne Kafaja24, Reem Jan25, Marcin Trojanowski26, Avram Goldberg27, Benjamin Korman28, James W. Thomas29, Elaine Remmers30, Adebowale Adeyemo7, Charles Rotimi7, Fredrick Wigley31, Francesco Boin32, Javier Martin3, Daniel Kastner33 and Pravitt Gourh34, 1Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, 3Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 4Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 6UTHealth Houston Division of Rheumatology, Houston, TX, 7Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 9Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 10Medical University of South Carolina, Charleston, SC, 11Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 12Georgetown University School of Medicine, Washington, DC, 13University of Michigan, Ann Arbor, MI, 14Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, 15New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, 16Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, 17Division of Rheumatology, Weill Cornell Medical College, New York, NY, 18Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, 19Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 20Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 21Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 22Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, 23Stanford University, Woodside, CA, 24Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 25Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, 26Department of Rheumatology, Boston University School of Medicine, Boston, MA, 27NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, 28University of Rochester, Rochester, NY, 29NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 30Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 31Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 32Cedars-Sinai Medical Center, Los Angeles, CA, 33National Human Genome Research Institute, Bethesda, MD, 34National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
  • Abstract Number: 2650 • ACR Convergence 2024

    Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis

    David Yang1, Quy Cao2, Fang Liu2, Tara McWilliams2, Ryan Rebello3, Madhura Tamhankar2, Shubhasree Banerjee2, Rui Liang2, Robert Kurtz2, Joshua Baker1, Naomi Amudala2, Zhaoyang Fan4, Jae Song2, Peter Merkel1, Jeffrey Morris2 and Rennie Rhee1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3St Joseph’s Hospital and McMaster University, Hamilton, ON, Canada, 4University of Southern California, Los Angeles, CA

    Background/Purpose: There is a need for measures of disease severity for giant cell arteritis (GCA), which may enable identification of high-risk subgroups (e.g., ophthalmic complications)…
  • Abstract Number: 0614 • ACR Convergence 2024

    Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient

    Background/Purpose: Improving quality of life (QoL) is one of the key targets when treating systemic lupus erythematosus (SLE) patients. The Lupus impact Tracker (LIT) is…
  • Abstract Number: 2652 • ACR Convergence 2024

    Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study

    Geoffroy Peyrac1, Natalie Lomba Goncalves1, Aïcha Kante2, Patrice Cacoub3, Karim Sacré4, David Saadoun5, Thomas Papo4, Jean-François Alexandra6, Valentin Pagis7, Venceslas Bourdin1, Pascal Richette8, Arnaud Vanjak9, Augustin Latourte10, Dikélélé Elessa7, William Bigot1, Ruxandra burlacu7, Karine Champion1, Blanca Amador Borrero7, Amanda Lopes1, Audrey Depond7, Peggy Reiner11, Homa Adle-Biassette12, Aude Couturier13, Philippe Bonnin14, Alexandre Boutigny15, Frédéric Paycha16, Anne Couvelard17, Alexis Régent18, Benjamin Chaigne19, Yann Nguyen20, Agnès lefort20, Olivier Bory21, Elisabeth Aslangul22, stephane mouly1, Damien Sène1, Viet-Thi Tran23 and Cloé Comarmond1, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 2Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 3Sorbonne Université, Paris, 4Université Paris Cité, Paris, France, 5Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, 6INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, 7Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, 8Lariboisière Hospital, Paris, France, 9Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, 10AP-HP, Paris, France, 11Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, 12Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, 13Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, 14Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 15Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, 16Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, 17Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, 18National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 19Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, 20Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, 21Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, 22Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, 23Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France

    Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
  • Abstract Number: 2624 • ACR Convergence 2024

    Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Jessica Neely1, Peter Shrader2, Stacey Tarvin3, Kaveh Ardalan4, Susan Shenoi5, Adam Huber6, Susan Kim7 and Hanna Kim8, and for the CARRA Registry Investigators, 1UCSF, San Francisco, CA, 2Duke Clinical Research Institute, Durham, NC, 3Indiana University School of Medicine, Indianapolis, IN, 4Duke University School of Medicine, Durham, NC, 5Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 6IWK Health Centre, Halifax, NS, Canada, 7University of California, San Francisco, CA, 8National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome.  Data from the…
  • « Previous Page
  • 1
  • …
  • 217
  • 218
  • 219
  • 220
  • 221
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology